FDA Stresses Dangers Of Transplant Drugs

Law360, New York (May 19, 2008, 12:00 AM EDT) -- Federal regulators warned again Friday that organ-transplant drugs made by Roche Holding AG and Novartis AG cause miscarriages and birth defects when taken by pregnant women.

The U.S. Food and Drug Administration initially released warnings and revised the labels for Roche's CellCept and Novartis' Myfortin drugs in November amid reports of miscarriages and ear and mouth deformities in infants after their mothers took the drugs to prevent organ rejection.

The drugs are used to suppress the body's immune system to avoid organ rejection in transplant patients....
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.